*Aveo Pharmaceuticals INC (Call) (AVEO) Stake Maintained by 683 Capital Management Llc

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Corporate LogoBig Money Sentiment increased to 2.11 in Q2 2018. It has change of 0.87, from 2018Q1’s 1.24. The ratio increased due to AVEO positioning: 15 sold and 12 reduced. 32 funds acquired positions and 25 increased positions. Investors holded 57.68 million in 2018Q1 but now own 59.55 million shares or 3.24% more. The New York-based 683 Capital Ltd Llc has invested 0.38% in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO). 311,034 were reported by Morgan Stanley. Creative Planning holds 0% or 63,100 shs. Comml Bank Of Montreal Can has 0% invested in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO). Evercore Wealth Management Lc, New York-based fund reported 418,414 shs. Savings Bank Of America Corporation De reported 0% in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO). Ameritas Investment invested 0% of its capital in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO). 20,640 were accumulated by Jpmorgan Chase & Company. Voya Invest Management Limited Liability Company invested in 0% or 37,820 shs. The Texas-based Utd Automobile Association has invested 0% in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO). Deer Vi & Lc holds 675,242 shs or 100% of its capital. Pnc Fincl invested in 0% or 27,000 shs. Credit Suisse Ag accumulated 0% or 28,399 shs. Hrt Financial Ltd Liability Company holds 20,477 shs or 0.02% of its capital. Winslow Evans And Crocker Incorporated reported 446 shs.

AVEO registered $29.81 million net activity with 52 insider buys and 0 insider sales since May 17, 2018. $491,745 worth of stock was bought by BARRIS PETER J on Wednesday, July 18. On Wednesday, May 30 Viswanathan Ravi had bought 275 shs worth $591. Sonsini Peter W. bought 236,479 shs worth $503,423. MAKOWER JOSHUA bought $591 worth of stock or 275 shs. 192,425 shs were bought by Puttagunta Chetan, worth $404,077. $503,423 worth of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) was bought by Florence Anthony A. Jr..

Based on the latest 2018Q2 regulatory filing with the SEC, 683 Capital Management Llc reduced its stake in Aveo Pharmaceuticals Inc (Call) (AVEO) by 80%. The company’s stock rose 29.82% with the market as 683 Capital Management Llc sold 2.00 million shares. The health care company at the end of 2018Q2 was priced at $1.13 million. It’s down from 2.50 million at the end of the previous reported quarter. Now it had 500,000 shares held by the hedge fund . $291.68M is Aveo Pharmaceuticals Inc (Call)’s MC. Ticker’s shares touched $1.86 during the last trading session after 7.00% change.AVEO Pharmaceuticals, Inc. has 4.91 million shares volume, 68.72% up from normal. AVEO is downtrending and has moved 19.14% since November 10, 2017. AVEO underperformed the S&P500 by 34.76%.

683 Capital Management Llc operates about $566.08M and $1.48 billion US Long portfolio. According to a filing the fund increased its stake in Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) by 110,000 shares to 300,000 shares, valued at $29.55 million in 2018Q2. For a total of 666,300 shares it increased its holding in Irsa Inversiones Y Rep S A (NYSE:IRS) by 194,008 shares in the quarter, and has risen its stake in Spdr Series Trust (Put) (XRT).

For more AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) news published recently go to: Seekingalpha.com, Seekingalpha.com, Businesswire.com, Seekingalpha.com or Seekingalpha.com. The titles are as follows: “Big Month For AVEO Pharmaceuticals Inc.” published on November 06, 2018, “AVEO Pharmaceuticals: A High Risk, High Reward Play” on October 16, 2018, “AVEO Reports Third Quarter 2018 Financial Results and Provides Business Update” with a publish date: November 09, 2018, “Vericel leads healthcare gainers; OncoSec Medical tops losers” and the last “AVEO Pharmaceuticals Enters A Critical Juncture Amid Stock Market Uncertainty. Will Its TKI-That-Could Prevail?” with publication date: October 12, 2018.

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.